Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15154484 | 0.86 | KEAP1 (0.54) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL15154571 | 0.85 | KEAP1 (0.52) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL15154632 | 0.83 | SMN1; SMN2 (0.50) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL10407793 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL646005 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL235080 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL6844349 | 0.77 | — | — | |
| SCHEMBL5345779 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL2595940 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 | |
| SCHEMBL21623672 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1GLASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | claimed |
| US-8952006-B2 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | XENOPORT, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2812319-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XenoPort, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | XENOPORT, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2013119791-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| US-5182278-A | Arterial hypotensive agents | ADIR ET COMPAGNIE (FR) | 1993-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | FH, APC, HTT | KDM4E 3249/4885ALDH1A1 2754/4885GLA 3983/4885 |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | FH, APC, HTT | KDM4E 3249/4885ALDH1A1 2754/4885GLA 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.